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tionally attributed to prosthetic valves as “valve-related
events” are, in fact, much more related to patient-relat-
ed factors, surgical technique, and postoperative man-
agement.2 Consequently, the results of valve replace-
ment with the same device differ markedly between
different population groups and especially between dif-
ferent age groups.3
Prosthetic valve assessment has been hindered by fail-
ure to take patient-related and management-related fac-
tors into account. In addition, cardiac surgeons’ views
have been colored by certain preconceptions about valve
design that have been incorporated by valve manufactur-
ers into their marketing strategy. There is a tendency to
categorize all types of mechanical valves into 3 design
categories (caged ball, tilting disc, and bileaflet) and to
make all-embracing generalizations about the character-
istics, sophistication, and modernity of each (ie, first gen-
eration, second generation). Worse still, and potentially
more dangerous, recommendations on anticoagulation
A t the start of the new millennium, successful heartvalve replacement has reached its fortieth anniver-
sary. Despite 40 years of this type of surgery, many
unanswered questions remain and the search continues
for the “perfect” replacement device. Given that even
native cardiac valves, although “perfect” in design, are
imperfect in terms of resistance to disease processes
and thrombus deposition,1 it is unlikely that a “perfect”
valve will ever be produced. Nevertheless, it is now
acknowledged that many of the “complications” tradi-
Objective: To assess the performance of the Medtronic Hall valve
(Medtronic, Inc, Minneapolis, Minn) in one institution over a 20-year
period.
Methods: Since 1979, Medtronic Hall valves have been used in 1766 proce-
dures (736 aortic, 796 mitral, and 234 double). Patients were followed up
prospectively at 6- to 12-month intervals for a total of 12,688 follow-up
years. Anticoagulation data (international normalized ratio) were recorded
for all patients (approximately 95,000 observations).
Results: Linearized rates of valve-related late death for aortic, mitral, and
double valve replacement were 0.8%/y, 0.9%/y, and 1.1%/y, respectively.
Risk factors for late mortality were (relative risk) diabetes (1.9), decade of
age (1.6), concomitant coronary artery bypass grafting (1.4), hypertension
(1.3), non-sinus rhythm (1.3), large valve size (1.1), valve regurgitation (1.3),
and male sex (1.2). For aortic, mitral, and double valve replacement, lin-
earized rates (percent per year) of adverse events were valve thrombosis
0.04, 0.03, and 0.0; all thromboembolism 2.3, 4.0, and 3.4; stroke 0.6, 0.8,
and 0.6; major hemorrhage 1.2, 1.4, and 1.6; and prosthetic endocarditis 0.4,
0.4, and 0.7. Risk factors for thromboembolism were (relative risk) mitral
valve replacement (1.9), diabetes (1.8), hypertension (1.5), and history of
embolism (1.4).
Conclusion: At 20 years the Medtronic Hall valve demonstrates excellent
durability, good hemodynamic performance, and very low thrombogenicity,
with a valve thrombosis rate lower than those reported for bileaflet designs.
With this prosthesis, both survival and thromboembolic events are predomi-
nantly determined by patient risk factors. (J Thorac Cardiovasc Surg
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management are often based on broad design categories
rather than individual prostheses.4,5
Because some of the early tilting disc valve designs
were susceptible to valve thrombosis, many assume that
this problem afflicts all tilting disc designs, whereas
analysis of available data shows that this is clearly not the
case.1 Similarly, bileaflet designs are perceived by many
as more “modern,” “third generation,” and less suscepti-
ble to the problems of thrombosis and thromboembolism;
however, some types of bileaflet valve have been shown
to be more prone to valve thrombosis than tilting disc
valves, especially in developing countries,6 and one
recently introduced bileaflet valve had to be withdrawn
from clinical use before trials were completed because of
its high susceptibility to valve thrombosis.7
The Medtronic Hall tilting disc valve (Medtronic,
Inc, Minneapolis, Minn) was introduced to clinical
practice in 1977, the same year as the St Jude Medical
bileaflet valve (St Jude Medical, Inc, St Paul, Minn).
Although both are widely regarded as safe, reliable
devices, it seems illogical that the latter is regarded by
some as more “modern.” A great deal of research and
development went into the refinement of the tilting disc
concept that eventually resulted in the production of the
Medtronic Hall valve.8 Unique design features were
incorporated to introduce very low susceptibility to
thrombosis. In comparison with previous tilting disc
designs, the relative size of the minor orifice was
increased and the disc was made to lift out of the hous-
ing and rotate on opening, all features designed to
improve washing of vulnerable points and eliminate
areas of low velocity flow. In addition, housing cross
members were placed in the center of blood flow and
shaped to avoid causing flow disturbance.
Dissatisfaction with earlier tilting disc valve designs
led to the introduction of the Medtronic Hall valve in
Cardiff in 1979, and its use continues today.
Methods
Patient population. The patients were predominantly from
South Wales, a region of the United Kingdom with much
social deprivation and high unemployment that has a relative-
ly high prevalence of both rheumatic and ischemic heart dis-
ease in relation to the rest of the United Kingdom and west-
ern Europe. Many of the Welsh patients, particularly the
female patients, are of small stature, reflecting a relatively
high requirement for small valve sizes. Use of the Medtronic
Hall valve began in December 1979. From that date until July
1994, 1981 Medtronic Hall valves were implanted in 1720
patients in 1766 procedures. Of these procedures, 736 (42%)
were aortic valve replacements (AVRs), 796 (45%) were
mitral valve replacements (MVRs), and 234 (13%) were dou-
ble valve replacements (DVRs), including some sequential
DVRs. The very small number of tricuspid valve replace-
ments (n = 12) and DVRs of mixed prosthesis type (n = 22)
were excluded from the analysis. Patients were included
whether the operation was performed on an elective or emer-
gency basis. Clinical variables are summarized in Table I and
operative data are shown in Table II.
Anticoagulation management. All patients received war-
farin, starting on the first postoperative day. Patients unable to
take oral warfarin at this time were given intravenous war-
farin until they could take medication orally. Patients were
given heparin only if their international normalized ratio
(INR) was less than 2.0 on the fourth postoperative day.
Individual INR measurements (approximately 95,000 obser-
vations) were recorded on all patients to carefully document
their anticoagulation experience in relation to adverse events.
The variation in INR values and the effect of an increase in
anticoagulation intensity on event rates in this series have
already been reported.9,10 Since the analysis in 1991, the tar-
get INR has been 2.5 for AVR (3.0 if the patient is in atrial
fibrillation or has poor left ventricular function) and 3.0 for
MVR and DVR.
In addition to warfarin, some patients received dipyri-
damole at the discretion of their own physicians, but there
was no prescribing consistency. Many patients discontinued
the drug because of side effects and those who took it did so
for only part of their follow-up. Overall, 13% of AVR
patients, 40% of MVR patients, and 32% of DVR patients
took dipyridamole for part of their follow-up. The percentage
of follow-up days taking dipyridamole was 7% for AVR, 28%
for MVR, and 23% for DVR.
Follow-up. In 1979, the Medtronic Hall valve was still a
relatively new prosthesis, and the first author (E.G.B.)
implanted the first Medtronic Hall valve in the United
Kingdom. This series was therefore planned as a prospective
observational study from the outset with follow-up data
recorded and entered into a computer at every outpatient visit
for each patient. Most patients attended follow-up clinics at
the University Hospital at intervals of 6 to 12 months. In the
case of patients attending follow-up clinics at other hospitals,
data were regularly retrieved from these sources also. At the
time of this analysis, the small number of patients who had
ceased to attend clinics regularly were contacted by tele-
phone to update their follow-up.
Patients were also “flagged” in the National Health Service
(NHS) Central Register, which maintains a death register for
the United Kingdom. The NHS Register then notified the
study investigators of all deaths of patients in the study and
provided a copy of the death certificate. The hospital records
of all patients who died in any hospital were scrutinized for
further details. A detailed analysis of deaths earlier in this
series has already been published,11,12 and the method of
using NHS Register notification has previously been validat-
ed.13 Autopsies were performed in 48% of all deaths and 70%
of sudden or unwitnessed deaths.11
Definitions and statistical analysis. For definitions of
mortality and morbidity, standard guidelines were used.14
Early events refers to events within the first 30 postopera-
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tive days. Late events refers to occurrences at all subse-
quent times.
Early events (<30 days) were expressed as percentages and
late events (>30 days) were expressed as percent per year. All
events, including those in the first 30 days, were included in
the event-free curves for mortality and morbidity. Right cen-
sored data, including patient survival, valve-related reopera-
tion, obstructive valve thrombosis, prosthetic endocarditis
leading to reoperation or death, and paravalvular leak were
constructed by means of the actuarial method of Kaplan and
Meier.15 Interval-censored data such as thromboembolism
and bleeding complications that were known to have
occurred during a particular interval of follow-up were
assessed by means of the Turnbull generalization of the
Kaplan-Meier method and by the conventional Kaplan-Meier
method taking the midpoint of follow-up intervals as the time
of failure. Because the 2 methods yielded very similar results,
probably because most intervals are small,16 we used the lat-
ter method. The significance of differences between groups
was tested by means of the log-rank method. The Weibull dis-
tribution model showed good agreement with the Kaplan-
Meier method to estimate the freedom from thromboem-
bolism. Instantaneous hazard functions of thromboembolism
were derived from the Weibull fits by taking the derivative of
the cumulative hazard function. The Cox proportional hazard
model was used to assess the relationship between various
risk factors and patient survival.17 All analyses were per-
formed using the SPLUS software package, version 2000
(MathSoft, Inc, Seattle, Wash).
Results
Early mortality. The operative mortality was 4.2%
for AVR, 7.7% for MVR, and 12% for DVR. There
were 2 early valve-related deaths (0.3%) in AVR
patients, 5 (0.6%) in MVR, and 1 (0.4%) in DVR
(Table III). Risk factors for early mortality were dia-
betes, previous valvotomy, concomitant coronary
artery bypass grafting, preoperative regurgitation, pre-
operative New York Heart Association (NYHA) class,
and decade of age (Table IV).
Follow-up. Follow-up information is summarized in
Table V. The total cumulative follow-up was 12,679
patient-years; 5120 patient-years for AVR (mean 7.0
years), 6053 patient-years for MVR (mean 7.6 years),
and 1506 patient-years for DVR (mean 6.6 years). With
follow-up to 1998, 64 patients were lost, for 96% com-
pleteness. The distribution of NYHA class preopera-
tively and at 5 (n = 979) and 10 (n = 419) years post-
operatively is shown in Fig 1. Analysis of functional
status changes showed an improvement in 69% of AVR
patients, 73% of MVR patients, and 74% of DVR
patients at 5 years. Improvement was sustained at 10
years in 66%, 64%, and 73%, respectively.
Survival. A total of 631 patients (211 AVR, 325
MVR, 95 DVR) died in the late postoperative period.
The late mortality expressed as linearized rate was
4.1%/y for AVR, 5.4%/y for MVR, and 6.3%/y for
DVR. Valve-related late death occurred in 40 (0.8%/y)
Table I. Clinical variables
AVR MVR DVR
No. of replacements 736 796 234
Male (%) 69 27 43
Age (y)
Mean ± SD 60 ± 11 57 ± 10 59 ± 9
Range 20-89 13-79 24-80
NYHA (%)
I-II 60 41 32
III-IV 40 59 68
Previous symptoms (%)
Angina pectoris 45 17 19
Orthopnea 42 71 72
Myocardial infarction 8 8 4
Heart failure 34 56 67
Atrial fibrillation/flutter 10 71 72
Thromboembolism 6 16 13
Concomitant disease (%)
Hypertension 21 12 12
Diabetes mellitus 5 7 6
Emergency operation (%) 10 7 6
Previous valve operation (%)
Valve repair/valvotomy 2 29 23
Valve replacement 5 8 18
Valve disease (%) A/M
Rheumatic 9 74 81/84
Endocarditis 5 2 3/2
Congenital 51 1 3/0
Ischemic 0 4 0/0
Degenerative 30 7 0.4/3
Valve calcification (%) 86 49 65/56
Operative diagnosis (%)
Stenosis 59 53 30/46
Regurgitation 21 26 42/26
Mixed lesion 20 21 28/28
A/M, Aortic position/mitral position
Table II. Operative data
AVR MVR DVR (A/M)
Prosthesis size (mm) (%)
20 13 0 23/0
21 23 0 33/0
22 3 0 1/0
23 31 4 26/3
25 21 23 12/20
27 8 32 4/41
29 2 31 1/28
31 0 8 0/7
33 0 2 0/1
Concomitant CABG (%) 21 14 14
A/M, Aortic position/mitral position.
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AVR patients, 53 (0.9%/y) MVR patients, and 17
(1.1%/y) DVR patients (Table III). Overall patient sur-
vivals, including early and late deaths, at 10 and 15
years were 64% and 45% for AVR, 58% and 36% for
MVR, and 47% and 30% for DVR (Fig 2). However,
survival was heavily influenced by the need for con-
comitant coronary surgery (Figs 3 and 4) and by valve
lesion (Figs 5 and 6). Survival after AVR for aortic
stenosis without coronary disease (Fig 5) was almost
identical to that for the age- and sex-matched general
population for the first 71⁄2 years (data from English
Life Tables, published by the United Kingdom Office
for National Statistics).
Risk factors for late mortality were diabetes, decade
of age, concomitant coronary artery bypass grafting,
hypertension, valve regurgitation, large valve size, non-
sinus rhythm, and male sex (Table VI).
Complications. There were no mechanical failures
and no cases of suture entrapment.
Thrombosis. Four patients had obstructive valve
thrombosis, 2 with AVR and 2 with MVR. Presentation
was insidious over several weeks in each case. Two
patients (1 AVR, 1 MVR) were treated by thrombecto-
my and 2 by re-replacement with another Medtronic
Hall valve. All 4 were postmenopausal women in their
70s. Three patients survived reoperation. The patient
who died had severely impaired left ventricular func-
tion caused by coronary disease and subendocardial
fibrosis. Valve thrombosis may have been a terminal
event associated with low cardiac output in this case.
The 3 remaining patients had all had anticoagulation
interruption: One diabetic patient had not received anti-
coagulants for 4 months after an intracerebral hemor-
rhage; one grossly obese patient with hypercholes-
terolemia had her warfarin stopped 3 times in the
course of a month in preparation for a minor orthope-
dic operation that was canceled twice; and an asthmat-
ic smoker receiving steroids had been given vitamin K
in addition to having the anticoagulation regimen inter-
rupted. All these patients also had pulmonary infec-
Table III. Valve-related deaths
AVR MVR DVR
Early (n) Late (n) Early (n) Late (n) Early (n) Late (n) 
Stroke 0 15 2 17 0 2
Thrombosis 0 1 0 0 0 0
Major bleeding 1 18 0 22 0 8
PVE 1 6 3 14 1 7
Total 2 (0.3%) 40 (0.8%/y) 5 (0.6%) 53 (0.9%/y) 1 (0.4%) 17 (1.1%/y)
Table IV. Logistic regression risk factors for early deaths
Coefficient SE P value RR
Preoperative NYHA class 0.442 0.186 .017 1.555
Diabetes 0.790 0.393 .045 2.203
Concomitant CABG 0.606 0.294 .040 1.833
Previous valvotomy 0.714 0.248 .004 2.042
Valve regurgitation 0.618 0.306 .043 1.855
Decade of age 0.343 0.145 .018 1.410
SE, Standard error; RR, relative risk; NYHA, New York Heart Association; CABG, coronary artery bypass grafting.
Table V.  Follow-up and death
AVR MVR DVR (A/M)
No. of valves 736 796 224/225
No. of valve replacements 736 796 234
No. of patients 726 779 226*
Operative mortality (%) 4.2 7.7 12
Lost patients 25 29 10
Follow-up
Maximum (y) 18 18 18
Mean ± SD (y) 7.0 ± 4 7.6 ± 5 6.5 ± 5
Total (pt-y) 5120 6053 1506
Completeness (%) 96.6 96.4 95.7
Late death
Total 211 325 95
Rate (%/y) 4.1 5.4 6.3
A/M, Aortic position/mitral position.
*Eleven sequential DVR patients also appear as previous AVR or DVR.
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tions in the period preceding the onset of valve throm-
bosis, raising the possibility that valve thrombosis was
due to a combination of a pre-existing prothrombotic
state, the prothrombotic effects of pulmonary infection,
and anticoagulation interruption. The detailed case his-
tories of all 4 patients and their risk factors for valve
thrombosis have already been described.18 No valve
thromboses occurred among the DVR patients. Among
the 70% of patients with sudden, rapidly progressing,
or unwitnessed death submitted to autopsy, there were
no cases of valve thrombosis.11 The linearized rates of
valve thrombosis were 0.04%/y for AVR and 0.03%/y
for MVR.
Thromboembolism. A total of 443 thromboembolic
events occurred in this series, 340 of which were minor,
almost all transient or reversible ischemic attacks (tran-
sient ischemic attacks or reversible ischemic neurologic
deficits); 103 were major (almost all strokes) that led to
permanent damage or death. The linearized rates of
minor events were 1.7%/y for AVR, 3.2%/y for MVR,
and 2.8%/y for DVR. The linearized rates of stroke were
0.6%/y for AVR, 0.8%/y for MVR, and 0.6%/y for DVR.
The linearized rates of overall thromboembolism were
2.3%/y for AVR, 4.0%/y for MVR, and 3.4%/y for DVR
(Table VII). Overall, 10% of patients had 1 thromboem-
bolic event and 6% had more than 1 event. Only 4% of
AVR patients and 5% of MVR patients had a stroke at
any time. In patients who had multiple events at 1 fol-
Fig 1. NYHA classification change at 5 and 10 postoperative
years.
Fig 2. Survival of patients by valve position.
Fig 3. Survival after AVR with and without coronary artery
bypass grafting. IAVR, First-time isolated AVR (n = 507); All,
all AVR (n = 735); AVR+CABG, First-time AVR with coro-
nary artery bypass grafting (n = 148).
Fig 4. Survival after MVR with and without coronary artery
bypass grafting. IMVR, First-time isolated MVR (n = 471);
All, all MVR (n = 796); MVR+CABG, first-time MVR with
coronary artery bypass grafting (n = 90).
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low-up interval, the linearized rate was computed in such
a way that applied the worst severity of the event to all
events. The overall actuarial estimates of freedom from
thromboembolism at 10 and 15 years were 84% and
79% for AVR, 77% and 65% for MVR, and 76% and
72% for DVR (Fig 7). Thromboembolism risk was high-
est during the first 30 days: computed as a “1-month”
linearized rate, it was 8%/y and 33%/y for AVR and
MVR, respectively. In contrast, the linearized rate for all
thromboembolism was 2%/y for AVR and 4%/y for
MVR after the first month, declining further during long-
term follow-up (Fig 8). Significant risk factors for
thromboembolism were MVR, diabetes, hypertension,
and a history of previous embolism (Table VIII).
Major hemorrhage. A total of 193 (69 AVR, 94
MVR, 24 DVR) major bleeding events met the defini-
tion of the guidelines.14 The linearized rates of major
hemorrhage were 1.2%/y for AVR, 1.4%/y for MVR,
and 1.6%/y for DVR. The actuarial estimates of free-
dom from major hemorrhage at 10 and 15 years were
87% and 83% for AVR, 87% and 81% for MVR, and
87% and 84% for DVR. The rate of major hemorrhage
also was highest in the early postoperative period, in
keeping with the known effect of anticoagulation in
unmasking occult disease.19,20
Prosthetic valve endocarditis. Prosthetic valve endo-
carditis developed in 59 patients, 33 of whom died (1 at
reoperation). The remainder had successful reopera-
tions. The linearized rates of endocarditis were 0.4%/y
for AVR, 0.4%/y for MVR, and 0.7%/y for DVR. The
actuarial estimates of freedom from endocarditis at 10
and 15 years were 96% and 95% for AVR, 95% and
94% for MVR, and 94% and 94% for DVR.
Paravalvular leaks. Paravalvular leak in the absence
of endocarditis occurred in 13 patients: 2 AVR, 9 MVR,
and 3 DVR, the latter all in the mitral position. The lin-
earized rates for AVR, MVR, and DVR were 0.04%/y,
0.1%/y, and 0.2%/y, respectively. The thin sewing ring
of the size 20 and 22 aortic prostheses was not associ-
ated with any paravalvular leaks. The actuarial freedom
Fig 5. Survival after AVR only, by valve lesion. Mixed, Mixed
lesions (n = 102); AS, aortic stenosis (n = 298); AR, aortic
regurgitation (n = 106).
Fig 6. Survival after MVR only by valve lesion. Mixed,
Mixed lesions (n = 91); MS, mitral stenosis (n = 273); MR,
mitral regurgitation (n = 106).
Table VI. Cox regression risk factors for late deaths
Coefficient SE P value RR
Hypertension 0.276 0.118 .019 1.318
Diabetes 0.618 0.149 .000 1.854
Concomitant CABG 0.306 0.111 .006 1.359
Valve size 0.065 0.017 .000 1.068
Valve regurgitation 0.239 0.089 .007 1.269
Decade of age 0.476 0.048 .000 1.610
Male sex 0.215 0.093 .021 1.240
Non-sinus rhythm 0.250 0.106 .019 1.284
SE, Standard error; RR, relative risk; CABG, coronary artery bypass grafting.
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from reoperation for paravalvular leak at 15 years was
99.7% for AVR, 99% for MVR, and 98% for DVR.
Reoperation and explantation. Any operation that
repaired, altered, or replaced a previously inserted valve
was called a reoperation. There were 58 reoperations (22
AVR, 25 MVR, 11 DVR), 48 of which (19 AVR, 21
MVR, 8 DVR) resulted in explantation. The linearized
rates of reoperation were 0.4%/y for AVR, 0.5%/y for
MVR, and 0.7%/y for DVR. The linearized rates of
explantation were 0.4%/y for AVR, 0.4%/y for MVR,
and 0.5%/y for DVR. The actuarial estimates of freedom
from reoperation at 15 years were 96% for AVR, 95%
for MVR, and 93% for DVR. The actuarial estimates of
freedom from explantation at 15 years were 96% for
AVR, 96.5% for MVR, and 94% for DVR. The reasons
for reoperation are listed in Table IX.
Table VII. Postoperative valve-related complications
AVR MVR DVR
Early (%) Late (%/y) Early (%) Late (%/y) Early (%) Late (%/y)
Thromboembolism 0.7 2.3 2.7 4.0 1.6 3.4
Minor 0.4 1.7 1.4 3.2 1.6 2.8
Major 0.3 0.6 1.3 0.8 0.0 0.6
Thrombosis 0.0 0.04 0.0 0.03 0.0 0.0
Major bleeding 0.8 1.2 1.1 1.4 0.0 1.6
PVE 0.1 0.4 0.4 0.4 0.4 0.7
Repair 0.0 0.04 0.0 0.1 0.4 0.2
Explant 0.1 0.4 0.0 0.3 0.0 0.5
Reoperation 0.1 0.4 0.0 0.4 0.4 0.7
PVE, Prosthetic valve endocarditis.
Fig 7. Thrombobembolism by valve position for AVR, MVR,
and DVR. The stepped curves are the Kaplan-Meier estimates
and the smooth curves are fitted from the parametric Weibull
distribution.
Fig 8. Instantaneous hazard function curves for thromboem-
bolism by valve position. The hazard functions are derived
from the Weibull fits (Fig 7) by taking the derivative of the
cumulative hazard function.
Table VIII. Cox regression risk factors for postoperative thromboembolism
Coefficient SE P value RR
MVR 0.635 0.156 .000 1.886
Diabetes 0.578 0.274 .035 1.783
Hypertension 0.397 0.193 .040 1.487
Previous embolism 0.324 0.087 .000 1.383
SE, Standard error; RR, relative risk.
with peak rate of increase of left ventricular dimen-
sion during diastole being used for the assessment.
These evaluations showed that the hemodynamic per-
formance of the Medtronic Hall valve was signifi-
cantly better than that of Björk-Shiley (Shiley, Inc,
Irvine, Calif) and Starr-Edwards prostheses (Baxter
Healthcare Corp, Edwards Division, Santa Ana, Calif)
of the same size, and left ventricular filling in 29- or
31-mm prostheses was not significantly different
from that of subjects with normal mitral valves. In
patients with 27-mm and 29- to 31-mm prostheses,
91% and 89%, respectively, improved by one class or
more.23 In the current analysis, the NYHA perfor-
mance status of most patients improved by at least
one class, an improvement that was maintained at 10
years. In patients whose dominant lesion was aortic
stenosis and who did not have coronary disease,
arguably the “purest” test of prosthesis performance,
survival was almost identical to that of the age- and
sex-matched general population for the first 71⁄2 years
and not significantly different from the general popu-
lation out to 10 years (Fig 5). This provides a com-
bined indirect assessment of hemodynamic effective-
ness and freedom from any excess of life-threatening
events in comparison with the general population.
Both characteristics of valve performance are proba-
bly attributable to optimum blood flow through the
prosthesis.
Optimum flow characteristics not only provide the
best relief of transvalvular gradients, allowing left ven-
tricular mass regression after AVR, for example, but
also, by providing good “washing” of all components
and minimizing flow disturbance, reduce the risk of
thrombus deposition and platelet activation.21 The
Medtronic Hall valve has been shown to have an equiv-
alent hemodynamic performance to the St Jude
Medical valve in the larger sizes and to have superior
hemodynamic performance to it in the smaller aortic
sizes,24 particularly with increasing cardiac output.25 It
is also possible to orientate the Medtronic Hall aortic
prosthesis so that the larger orifice faces the greater
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All valve-related complications. The linearized
rates of all valve-related complications were 4.3%/y for
AVR, 6.2%/y for MVR, and 6.4%/y for DVR. The actu-
arial estimates of freedom from all valve-related com-
plications at 10 and 15 years were 72% and 60% for
AVR, 61% and 50% for MVR, and 61% and 52% for
DVR.
Discussion
The most important variables that measure prosthetic
valve performance and permit meaningful comparison
between prostheses are mechanical integrity, hemody-
namic characteristics, and thrombogenicity, inasmuch
as these are truly prosthesis-related factors, specific to
the type of prosthesis, which influence survival and
quality of life. Other adverse events that occur after
valve replacement and that are classified by the report-
ing guidelines14 as “prosthesis related,” for example,
endocarditis and major hemorrhage, are events that
occur in all large prosthetic valve series but are not
“caused” by the specific type of prosthesis; rather, they
are prosthesis associated but much more related to
patient factors and aspects of postoperative manage-
ment, particularly in the case of hemorrhage, the qual-
ity of anticoagulation control, and the target INR range.
Durability and hemodynamic performance can be mea-
sured according to rigid objective criteria, but throm-
bogenicity is difficult to measure. It has been shown
that thromboembolic rates vary considerably among
different series of the same prosthesis,3 probably
because of differences in patient population (age, eth-
nicity, geography, and concomitant disease), antithrom-
botic management, and methods of data collection.21
Thromboembolic rates after valve replacement have
also been shown to be heavily influenced by known
stroke risk factors.22 Hence, thromboembolic rates pro-
vide a poor measure of thrombogenicity unless
allowances can be made for all other influences in the
analysis. We have used this approach in earlier analyses
(vide infra). Although also to some extent dependent on
patient factors and anticoagulation management, valve
thrombosis rates give a much better indication of pros-
thesis thrombogenicity.21
The goal of the Medtronic Hall design was to
improve on previous tilting disc designs with the aim
of improving durability and hemodynamic perfor-
mance and reducing thrombogenicity. The results of
this 20-year experience show that these aims have
been achieved. There were no mechanical failures.
Hemodynamic measurements were not performed on
all patients, but echocardiographic assessment of
mitral prostheses was carried out early in the study,
Table IX.  Reasons for reoperation
AVR MVR DVR
Endocarditis 17 13 7
Paravalvular leak 2 9 3
Thrombosis 2 2 0
Tissue ingrowth 0 1 1
Recurrent embolism 1 0 0
Total 22 25 11
coronary artery disease had no cerebrovascular
events during a 13-year follow-up period.22
The mitral prosthesis in this series was implanted
with the larger orifice posteriorly in almost all patients.
This orientation has been shown to permit flow patterns
within the left ventricle similar to those seen physio-
logically35 and probably contributed to the almost nor-
mal rate of ventricular filling seen with the larger sized
mitral prostheses referred to above.23
Thromboembolic events after mitral valve replace-
ment are determined largely by conditions that promote
relative stagnation in the left atrium (atrial fibrillation,
increased left atrial size, residual mitral gradient, and
impaired left ventricular function) and the extent to
which these adverse conditions are controlled by effec-
tive anticoagulation.21 In earlier analyses, we have
shown that the optimum INR of 3.0 prevents most seri-
ous thromboembolic events in patients with the
Medtronic Hall valve in the mitral position10 and that
the incidence of events has an association with known
stroke risk factors and a seasonal fluctuation with win-
ter predominance, in keeping with pulmonary infection
as a trigger factor.36
Much earlier in this series, we reported a zero rate of
valve thrombosis with the Medtronic Hall valve. At that
stage, in 1988, in just over 1000 patients, there had
been no cases of valve thrombosis.37 Since then 4
patients have had obstructive valve thrombosis, but the
overall incidence remains extremely low (0.04%/y). A
previously published analysis of these patients identi-
fied the combination of the prothrombotic effects of
pulmonary infection and anticoagulation interruption
as the probable interaction that triggered thrombus
deposition on the prosthesis in 3 of 4 patients.18
The valve thrombosis rate reported here is lower than
that reported for other large series of mechanical valves
and some series of bioprostheses with comparable
lengths of follow-up.3 Eleven of 12 St Jude Medical
mitral valve series with more than 300 valve-years
reported since 1989 had higher thrombosis rates. For
these 11 series with a total of 28,000 years, the mean
thrombosis rate was 0.13%/y (range 0.07%/y-
0.45%/y).3
The very good thromboembolic performance of the
Medtronic Hall valve in this series has been achieved
with low-intensity anticoagulation, giving the addition-
al benefit of a low incidence of serious bleeding events.
To place it in context, this needs to be compared with
the background incidence of major hemorrhage in the
general population. Data from the placebo arms of sev-
eral anticoagulation trials show that major hemorrhage
occurs at a linearized rate between 0.7%/y and 1.6%/y
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curvature of the ascending aorta, thereby creating near-
physiologic flow.26,27 The same can never be achieved
with a bileaflet valve, because it has 3 orifices26; con-
sequently, valve gradients across the Medtronic Hall
valve in its optimum orientation are lower than can be
achieved with the St Jude Medical valve in any orien-
tation.28 This improved and less turbulent flow in com-
parison with the bileaflet design may contribute to the
trend toward greater left ventricular mass regression
that has been reported with the Medtronic Hall valve in
comparison with the St Jude Medical valve.29 It may
also partly explain the finding of less hemolysis with
the Medtronic Hall valve when normally functioning
Medtronic Hall and St Jude Medical valves are com-
pared.30 Anderson and associates31 have shown nor-
malization of left ventricular mass index after AVR
with the Medtronic Hall valve, using ultrafast comput-
ed tomographic scan, even in the smallest sizes 20 and
21. Furthermore, a recent study has shown more rapid
left ventricular mass regression with the Medtronic
Hall valve in comparison with the St Jude Medical
valve after AVR.32
In the series reported here, the aortic valve was
implanted preferentially with the larger orifice
toward the greater curvature of the aorta, rotating the
valve only if this position caused the downward
deflection of the disc to impinge on the septum. The
majority of aortic prostheses (89.1%) were thus in
the optimum orientation. The good long-term sur-
vival after AVR in comparison with the general pop-
ulation in this series may relate to the very low tur-
bulence and low gradients produced by the prosthesis
in this orientation. In an earlier analysis, we have
shown that the gradually increasing incidence of
stroke with advancing age in this series did not differ
significantly from the age-related background inci-
dence of stroke in the general population.33 This find-
ing may also reflect the beneficial effect of optimum
flow in combination with low thrombogenicity.
Transcranial Doppler detection of high-intensity
transient signals has recently shown significantly
fewer high-intensity transient signals with the
Medtronic Hall valve in its optimum orientation both
in comparison with its worst orientation and in com-
parison with the St Jude Medical valve in any orien-
tation, in keeping with this hypothesis.34 Using data
from earlier analysis of this series, we have shown
that cerebrovascular events after AVR were closely
related to well known stroke risk factors, that is,
hypertension, cigarette smoking, diabetes, and arteri-
al disease. Patients who were in sinus rhythm, nor-
motensive, nonsmokers, not diabetic, and who had no
(mean 1.2%/y) in a population of approximately the
same age group as this valve series.38-40 The linearized
rates for AVR, MVR, and DVR (1.2%/y, 1.4%/y, and
1.6%/y, respectively) fall within the range in the gener-
al population, indicating that the patients in this series
were not exposed to an excess risk as the result of their
anticoagulation management.
Overall, our results at 20 years demonstrate that the
Medtronic Hall valve has excellent durability, very good
hemodynamic performance, and exceptionally low
thrombogenicity, leading to good long-term survival with
low complication rates and a very low requirement for
reoperation. Contrary to the perceptions of many surgeons
about the supposed design advantages of bileaflet valves,
our long-term results support the large number of recent
reports showing that more physiologic flow conditions
can be created by the Medtronic Hall valve. In our view
this prosthesis offers superior hemodynamic performance
and lower thrombogenicity than currently available
bileaflet designs and should now be considered the gold
standard against which other prostheses should be judged.
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